Nishimoto Yuichiro, Fujisawa Kota, Ukawa Yuichi, Kudoh Masatake, Funahashi Kazuki, Kishimoto Yoshimi, Fukuda Shinji
Metagen Inc., Tsuruoka, Japan.
Department of Life Science and Technology, Tokyo Institute of Technology, Tokyo, Japan.
Front Nutr. 2023 Jan 5;9:1077534. doi: 10.3389/fnut.2022.1077534. eCollection 2022.
Urolithin A (UA) is a metabolite produced by gut microbiota from ingested ellagic acid. Although the effect of ellagic acid intake on vascular endothelial function (VEF) improvement has been reported, the effect of UA intake on VEF improvement remains obscure. In addition, UA has been reported to improve the intestinal barrier function, and UA may have improved VEF by gut microbiome alteration.
In this study, we conducted a clinical trial to explore and analyze the effects of UA intake on vascular endothelial function (VEF) and characteristics of the intestinal environment, such as gut microbiome profiling and organic acid composition.
A placebo-controlled, randomized, double-blinded, parallel group trial was conducted on participants who could metabolize small amounts of UA from ellagic acid (non-UA producers) and had relatively poor VEF. VEF was assessed using the flow-mediated vasodilatation (FMD) score. Participants were administered placebo, UA 10 mg/day, or UA 50 mg/day for 12 weeks. FMD was measured and fecal samples were collected at 0, 4, 8, and 12 weeks of treatment. Gut microbiome analysis and organic acid level measurements were performed to evaluate the effects of UA intake on the intestinal environment. This clinical trial is publicly registered at the UMIN-CTR, trial number: UMIN000042014.
The gut microbiota of the UA 50 mg/day group showed a significant increase in alpha diversity (Faith's phylogenetic diversity). Four and nine microbial genera were significantly altered in the UA 10 mg/day and UA 50 mg/day groups, respectively ( < 0.05, not corrected). Participants whose FMD scores improved with UA intake had poor baseline FMD values as well as a low Bacillota/Bacteroidota ratio.
Urolithin A intake alters the gut microbiota and improves their alpha diversity. In addition, the effect of UA on VEF correlated with the individual gut microbiota. Our results have practical implications for a new approach to providing healthcare that focuses on intestinal environment-based diet therapy.
尿石素A（UA）是肠道微生物群从摄入的鞣花酸产生的一种代谢产物。虽然已有报道摄入鞣花酸对改善血管内皮功能（VEF）有作用，但摄入UA对改善VEF的作用仍不明确。此外，有报道称UA可改善肠道屏障功能，且UA可能通过改变肠道微生物群来改善VEF。
在本研究中，我们进行了一项临床试验，以探索和分析摄入UA对血管内皮功能（VEF）以及肠道环境特征（如肠道微生物群谱和有机酸组成）的影响。
对能够从鞣花酸代谢少量UA（非UA产生者）且VEF相对较差的参与者进行了一项安慰剂对照、随机、双盲、平行组试验。使用血流介导的血管舒张（FMD）评分评估VEF。参与者被给予安慰剂、10毫克/天的UA或50毫克/天的UA，持续12周。在治疗的0、4、8和12周测量FMD并收集粪便样本。进行肠道微生物群分析和有机酸水平测量，以评估摄入UA对肠道环境的影响。该临床试验已在UMIN-CTR公开注册，试验编号：UMIN000042014。
50毫克/天UA组的肠道微生物群显示α多样性（费思系统发育多样性）显著增加。1G在10毫克/天UA组和50毫克/天UA组中分别有4个和9个微生物属发生了显著改变（P<0.05，未校正）。FMD评分随UA摄入而改善的参与者基线FMD值较低，且芽孢杆菌门/拟杆菌门比率也较低。
摄入尿石素A会改变肠道微生物群并改善其α多样性。此外，UA对VEF的影响与个体肠道微生物群相关。我们的结果对一种以肠道环境为基础的饮食疗法的新医疗保健方法具有实际意义。 1. “1G”疑似有误，原文未提及该内容，翻译时保留原文。
